Morbidity in transsexual patients with cross-gender hormone self-treatment;Morbilidad en pacientes transexuales con autotratamiento hormonal para cambio de sexo

Medicina Clinica

Volumn 113, Issue 13, 1999, Pages 484-487

  Fernández, Antonio Becerra ^a,b   De Luis Román, Daniel Antonio ^a   Maroto, Gonzalo Piédrola ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE   (Spain)

Author keywords

Cardiovascular risk; Cross gender; Hormone treatment; Hyperprolactinemia; Side effects; Transsexual

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; ESTRADIOL ENANTHATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL;

ADULT; ANDROGEN THERAPY; ARTICLE; ESTROGEN THERAPY; FEMALE; GENDER; HORMONAL THERAPY; HUMAN; HYPERPROLACTINEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; SELF MEDICATION; TRANSSEXUALISM;

ADOLESCENT; ADULT; CHOLESTEROL; CROSS-SECTIONAL STUDIES; CYPROTERONE; ENZYMES; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPERPROLACTINEMIA; LIVER; MALE; MORBIDITY; PREVALENCE; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; SELF MEDICATION; SEX REVERSAL, GONADAL; SPAIN; TRANSSEXUALISM;

EID: 0033598657     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Eklund PLE, Gooren LJG, Bezemer PD. Prevalence of transsexualism in the Netherlands. Br J Psychiatry 1988; 152: 641-648.
2. Hamburguer C. Endocrine treatment of male and female transsexualism. En: Green R, Money J, editores. Transsexualism and Sex Reassignment. Baltimore: John Hopkins University 1969; 291-307.
3. Van Kesterin PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-342.
4. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-618.
5. Royal College of General Practitioners Oral Contraception Study: Mortality among oral-contraceptive users. Lancet 1977; 2: 727-731.
6. Vischer U. Estrogens and atherosclerosis: a direct protective effect on the vascular wall? Eur J Endocrinol 1997; 137: 343-344.
7. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate Surg Gynecol Obstet 1967; 124: 1.011-1.017.
8. Wilson JD, Griffin JE. The use and mis-use of androgens. Metabolism 1980; 29: 1.278-1.295.
9. Walker PA, Berger JC, Green R, Laub DR, Reynolds CL, Wollman L. Standards of care. The hormonal and surgical sex reassignment of gender dysphoric persons. Arch Sex Behav 1985; 14: 79-90.
10. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1988; 21 (Supl 1): 5-16.
11. Friedewald WT, Levy IR, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without the use of preparative ultracentrifugation. Clin Chem 1972; 18: 499-509.
12. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence to atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-737.
13. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997; 37: 477-515.
14. Moffatt R, Wallace M, Sady S. Effects of anabolic steroids on lipoprotein profiles of female weight lifters. Physician Sports Med 1990; 18: 106-110.
15. Märin P, Krotkiewski M, Björntorp P. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. Eur J Int Med 1992; 1:329-336.
16. Gooren LJG. Testosteron: a good-hearted hormone? En: Abstract book of Satellite Symposium on testosterone replacement therapy of IV European Congress of Endocrinology, Sevilla, 1998; 13.
17. Asscheman H, Gooren UG, Eklund PLE. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 1989; 38: 869-873.
18. Gooren LJG. The endocrinology of transexualism: a review and commentary. Psychoneuroendocrinology 1990; 15: 3-14.
19. Pérez RL, Machiavelli GA, Romano MI, Burdman JA. Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats. J Endocrinol 1986; 108: 399-403.
20. Ben Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocrine Rev 1985; 6: 564-589.
21. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 1985; 65: 506-510.
22. Gooren LJG, Harmsen-Louman W, Van Kessel H. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol (Oxf) 1985; 22: 201-207.
23. Asscheman H, Gooren LJG, Assies J, Smits JPH, De Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 1988; 28: 583-588.
24. Gooren LJG, Assies J, Asscheman H, De Slegte R, Van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metabol 1988; 66: 444-446.
25. Kovacs K, Stefaneau L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A study morphologic study. Arch Pathol Lab Med 1994; 118: 562-565.
26. Gooren L, Van der Veen EA, Van Kessel H. Modulation of prolactin secretion by gonadal steroids in men. En: MacLeod RM, Scampagnini V, editores. Central and peripheral regulation of prolactin function. Nueva York: Raven Press, 1980; 373.